Insulet recalls millions of Omnipod 5 pods over cannula defects that cut insulin

Insulet has recalled Omnipod 5 insulin pods in two separate Class I actions this year after discovering that the pods' soft cannula — the small tube that carries insulin under the skin — can be damaged during manufacturing, causing the hormone to leak rather than be delivered [s1][s2]. Class I is the Food and Drug Administration's most serious recall category, reserved for defects it judges could cause serious injury or death.

The larger action, recall number Z-2603-2026, covers 4,936,056 pods distributed worldwide, including across the United States and some two dozen other countries [s1]. Insulet began it on 20 May 2026, and the FDA posted the enforcement report on 8 July 2026 [s1]. Both recalls remain listed as ongoing, and both were initiated by the company rather than ordered [s1][s2].

Two defects, one consequence

The two recalls describe related but distinct manufacturing faults. In the May action, damage during manufacturing leaves the soft cannula able to leak insulin around the pod "instead of being delivered to the user regardless of basal or bolus delivery" [s1]. The earlier action, Z-1797-2026, involves an internal tear in the cannula that lets insulin leak inside the pod; it covers 49 lots and 1,240,115 pods distributed nationwide, and the FDA posted it on 22 April 2026 [s2].

In both cases the main failure mode is the same: the pump under-delivers insulin because some of the dose is lost to a leak [s1][s2]. The agency's notice spells out the stakes. Under-delivery or cessation of insulin "put users at risk of hyperglycemia, and complications from acute and chronic hyperglycemia, including dehydration, blurry vision, nausea, vomiting, altered mental status, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death" [s2]. The later notice uses almost identical language, warning that in the most severe cases "prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death" [s1].

The warning may not sound

The harder problem for users is detection. The FDA states that "not all devices with the defect will issue an alarm or alert the user" [s2]. In the internal-leak scenario, a pod will sound a hazard alarm and stop insulin only if enough insulin leaks to short the pod's circuitry [s2]. Short of that, the system may eventually trigger an Automated Delivery Restriction alert — but that is a response to persistent high glucose and its own delivery limits, "rather than a direct detection of the leak" [s2]. The agency adds that the magnitude of under-delivery is unknown and depends on how much insulin is being given, whether an alarm fires, how soon the user notices, how long the pod has been worn and the size of the tear [s2].

That uncertainty is the point. A pod that quietly delivers less than intended, without a clear alarm, is harder to catch than one that fails outright — and rising glucose can be mistaken for an ordinary bad day of control.

How to read it

A recall of this size in a device people rely on continuously is serious, but the enforcement reports describe a manufacturing defect confined to identified lots, not a flaw in the Omnipod 5 design itself [s1][s2]. The documents list specific model, reference, UDI and lot numbers, which is how users and clinicians can tell whether a given supply is affected [s1][s2]. The May action spans several reference numbers — among them POD-OMNI-I1-6720 and OMNI-I1-6220 — with a single-pod device identifier of 10385083000527, the same identifier that appears in the earlier nationwide recall [s1][s2].

There is a second layer of nuance in the earlier, internal-leak recall. If enough insulin leaks to short the pod's circuitry, the device issues a hazard alarm that halts all insulin delivery — a fail-safe, but one that itself leaves a user without automated insulin until the pod is replaced [s2]. The failure can therefore present either as silent under-delivery or as an abrupt stop, two very different experiences for someone managing diabetes hour to hour.

What to watch

Whether Insulet's corrections reach users quickly, and whether reported harms track the FDA's concern, will show in future updates to these ongoing recalls [s1][s2]. Pod users with questions about affected lots should check the recall notices and contact the manufacturer or their clinician rather than change therapy on their own.

This article describes a device-safety action and is not medical advice. Do not stop or alter insulin therapy without guidance from your clinician. Seek urgent care for symptoms of very high blood sugar — excessive thirst, frequent urination, nausea or vomiting, confusion, or difficulty breathing.

Sources

• Enforcement Report Z-2603-2026: Omnipod 5 Pods, Class I recall (external soft cannula damage) — U.S. Food and Drug Administration, report posted 8 July 2026
• Enforcement Report Z-1797-2026: Omnipod 5 Pods, Class I recall (internal soft cannula tear) — U.S. Food and Drug Administration, report posted 22 April 2026